First-line treatment of patients with metastatic colorectal cancer: An overview of recent data on chemotherapy plus targeted agents

Clinical Colorectal Cancer

Volumn 7, Issue SUPPL. 2, 2008, Pages

  Cercek, Andrea ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; K ras; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; LEUKOPENIA; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; RASH; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; ONCOGENE RAS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; GENES, RAS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58949099694     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.s.007     Document Type: Article

References (33)

1. Punt CJ, Koopman M, Douma J, et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study. J Clin Oncol 2007; 25(18 suppl):166s (Abstract 4012).
2. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
3. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
5. Skillings JR, Johnson DH, Miller K, et al. Arterial thrombotic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005; 23(16 suppl):196s (Abstract 3019).
6. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxali- platin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study [published erratum appears in: J Clin Oncol 2008; 26:3110]. J Clin Oncol 2008; 26:2013-9.
7. Purdie DM, Berlin JD, Flynn PJ, et al. The safety of long-term bevacizumab use: results from the BRiTE observational cohort study (OCS). J Clin Oncol 2008; 26(15 suppl):203s (Abstract 4103).
8. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008 [Epub ahead of print].
9. Kozloff M, Sugrue M, Berlin J, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (mCRC): results from the BRiTE prospective cohort study. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 454.
10. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irino- tecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-86.
11. Fuchs, CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26:689-90.
12. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-75.
13. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7(suppl 4):2-8.
14. Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002; 16:1041-63.
15. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related pep- tides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
16. Saltz LB, Rubin M, Hochester H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract 7).
17. Saltz L, Meropol NJ, Loeher PJ, et al. Single agent IMC-C225 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21: (Abstract 504).
18. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetux- imab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
19. Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005; 11:397-405.
20. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 2004; 22:248 (Abstract 3511).
21. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3548).
22. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitu- mumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
23. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinote- can and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
24. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxali- platin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25(18 suppl):172s (Abstract 4035).
25. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006; 12:2197-207.
26. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-61.
27. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of safety and efficacy of oxali- platin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 273.
28. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorec- tal cancer (ACC), the CAIRO2 study if the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26(15 suppl):180s (Abstract LBA4011).
29. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-7.
30. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9.
31. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitu- mumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34.
32. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first- line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26(15 suppl):5s (Abstract 2).
33. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008; 26(15 suppl):178s (Abstract 4000).